In October, J&J EVP and J&J MedTech Worldwide Chair Ashley McEvoy announced her resignation from the world’s second-largest device manufacturer. She’s staying on into the first quarter of 2024 while her successor, Tim Schmid, gets settled into his new role.
Schmid, a 30-year J&J vet who was most recently company group chair of J&J MedTech Asia Pacific, said he’s “committed to building even further on the progress we’ve already made.”
“While I recognize that we have more work to do, I’m focused on further advancing our impact and our competitiveness,” he said this month. “Our goal is clear. It is to be No. 1 or No. 2 in every market that we compete.”
Here are more of the top medtech personnel moves of 2023 since our last round-up this summer:
Zimmer Biomet CEO leaves to lead 3M HealthCare spinoffBryan Hanson on Aug. 22 departed the corner office at Zimmer Biomet to become CEO of 3M’s soon-to-be-completed healthcare business spinoff. This move set in motion a series of executive changes at both companies and across medtech.
Zimmer Biomet named Ivan Tornos as its new CEO and made other changes to its leadership team. 3M, meanwhile, hired Insulet CFO Wayde McMillan to lead the spinoff’s financial operations, while 3M HealthCare President Jim Lavers departed to make way for Hanson.
Illumina picks a new CEO amid SEC investigation
Following the resignation of Francis deSouza in June, DNA sequencing technology developer Illumina named Jacob Thaysen as its new CEO. Thaysen joined from Agilent Technologies as Illumina seeks to move beyond regulatory scrutiny of its acquisition of Grail.
Shockwave Medical hires Abbott exec as CMO
Intravascular lithotripsy (IVL) technology developer Shockwave Medical said in September that it named Dr. Nick West as its CMO-in-waiting. The former CMO and divisional VP of global medical affairs at Abbott Vascular will take over for Dr. Keith Dawkins in mid-2024.
Medtronic has a new neuromodulation president
In October, Medtronic appointed Paolo Di Vincenzo as the president of its neuromodulation business. Di Vincenzo joined from Smith+Nephew, where he served as SVP and GM of U.S. advanced wound management. He spent nine years at the orthopedic giant.
Silk Road Medical has a new CEOSilk Road Medical announced in October that CEO Erica Rogers intended to retire. Weeks later, the company named a replacement: Chas McKhann. McKhann has 25 years of experience, including as CEO of Apollo Endosurgery, which Boston Scientific acquired for $615 million in April.
Cordis puts board chair in the corner office
Orthofix picks new CEO after terminating trio of execs
Orthofix said Massimo Calafiore will be its new CEO starting in early 2024. He’s currently CEO of LimaCorporate and will join Orthofix following the completion of Lima’s acquisition by Enovis. Calafiore’s appointment follows the September termination with cause of CEO Keith Valentine and two other executives.
Distalmotion selects former Zimmer Biomet exec as CEO
Switzerland-based Distalmotion this month appointed Greg Roche as its CEO as the company looks to continue commercial expansion for its surgical robot. Roche most recently served as CEO of soft tissue robotics company AvateraMedical, and before that was global president of robotics and technology at Zimmer Biomet.
Medical Design & Outsourcing: How does medtech CEO pay stack up to the rank and file?
— Managing Editor Jim Hammerand contributed to this report.